Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2010

View Archived Issues

Xcellerex initiates phase I trial of yellow fever vaccine

TGen Drug Development and Critical Outcome Technologies to collaborate on COTI-2

FDA grants Octapharma's Wilate orphan drug exclusivity for von Willebrand's disease

Karolinska Development and BioChromix form BioChromix Pharma

BioCryst achieves enrollment target in pivotal forodesine study

Novavax reports results from preclinical study of RSV vaccine in rats

CeNeRx BioPharma reports clinical results on CXB-722 in disorders of central nervous system

VaxInnate licenses recombinant H1N1 vaccine to Biological E. in India

New agents partially inhibit PDE4 and display reduced toxicity

Spherix completes enrollment into phase III trial of D-tagatose in type 2 diabetes

mTOR inhibition restores age-impaired hematopoietic stem cell function

NP-04634 shows anticonvulsant activity in rodent model of status epilepticus

Alogliptin equally effective in younger and elderly patients with type 2 diabetes

Trillium grants Biogen Idec exclusive worldwide rights to its development program

European orphan drug status recommended for Protalix's taliglucerase alfa for GD

FDA extends review period for OSI's sNDA for Tarceva in non-small cell lung cancer

Celgene acquires Gloucester Pharmaceuticals

Genentech claims checkpoint kinase Chk1 inhibitors for cancer therapy

GlaxoSmithKline presents PI3K inhibitors for treatment of asthma and COPD

Novel PPAR agonists claimed by sanofi-aventis as antidiabetic agents

Takeda's orally disintegrating Actos tablets approved in Japan for type 2 diabetes

Stearoyl-CoA desaturase inhibitors for treatment of acne claimed by GlaxoSmithKline

Merck & Co. discovers fatty-acid amide hydrolase inhibitors for postherpetic neuralgia

Novel protein kinase inhibitors for the treatment of cancer presented by sanofi-aventis

Bayer Yakuhin and Hospira Japan enter marketing agreement for Shinbit

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...